Crataegus special extract WS® 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion

Life Sciences

Volumn 74, Issue 15, 2004, Pages 1945-1955

  Veveris, Maris ^a   Koch, Egon ^b   Chatterjee, Shyam S ^b  

^a LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

^b DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

Author keywords

Cardioprotection; Crataegus extract WS 1442; Ischemia; Myocardial infarction; Reperfusion

Indexed keywords

CRATAEGUS EXTRACT; FLAVONOID; PLANT EXTRACT;

ANALYSIS OF VARIANCE; ANIMAL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; CRATAEGUS; DOSE RESPONSE; DRUG EFFECT; ELECTROCARDIOGRAM; HEART; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; LEFT CORONARY ARTERY; LOW DRUG DOSE; MALE; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; RAT STRAIN; REPERFUSION INJURY; ST SEGMENT ELEVATION;

CRATAEGUS;

EID: 0842324493     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.09.050     Document Type: Article

References (34)

1. Al Makdessi S., Sweidan H., Dietz K., Jacob R. Protective effect of Crataegus oxyacantha against reperfusion arrhythmias after global no-flow ischemia in the rat heart. Basic Research in Cardiology. 94(2):1999;71-77.
2. Anversa P., Cheng W., Liu Y., Leri A., Redaelli G., Kajstura J. Apoptosis and myocardial infarction. Basic Research in Cardiology. 93(Suppl. 3):1998;8-12.
3. Baxter G.F., Ebrahim Z. Role of bradykinin in preconditioning and protection of the ischaemic myocardium. British Journal of Pharmacology. 135(4):2002;843-854.
4. Blumenthal M., Busse W.R., Goldberg A., Gruenwald J., Hall T., Riggins C.W., Rister R.S. The Complete German Commission E Monographs. Therapeutic Guide to Herbal Medicine. 1998;Integrative Medicine Communications, Austin.
5. Bolli R. Oxygen-derived free radicals and myocardial reperfusion injury: an overview. Cardiovascular Drugs Therapy. 5(Suppl. 2):1991;249-268.
6. Bolli R. The late phase of preconditioning. Circulation Research. 87(11):2000;972-983.
7. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade research. Journal of Molecular and Cellular Cardiologie. 33(11):2001;1897-1918.
8. Chang Q., Zuo Z., Harrison F., Chow M.S.S. Hawthorn. Journal of Clinical Pharmacology. 42(6):2002;605-612.
9. Chatterjee S.S., Koch E., Jaggy H., Krzeminski T. In vitro and in vivo investigations on the cardioprotective effects of oligomeric procyanidins of a Crataegus extract from leaves with flowers. Arzneimittel Forschung/Drug Research. 47(7):1997;821-825.
10. Chatterjee S.S., Porc M., Krzeminski T.F. Effects of Crataegus oxyacantha extract (WS-1442) and its fractions against myocardial reperfusion injuries. Naunyn-Schmiedeberg's Archives of Pharmacology. 358(Suppl. 2):1998;R488.
11. Flameng W., Vanhaecke J., Vandeplassche G. Studies on experimental myocardial infarction: dogs or baboons? Cardiovascular Research. 20(4):1986;241-247.
12. Gobel F.L., Norstrom L.A., Nelson R.R., Jorgensen C.R., Wang Y. The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. Circulation. 57(3):1978;549-556.
13. Hearse D.J. Myocardial ischemia: can we agree on a definition for the 21st century? Cardiovascular Research. 28(12):1994;1737-1744.
14. Howard B.V., Kritchevsky D. Phytochemicals and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation. 95(11):1997;2591-2593.
15. Jordan J.E., Zhao Z.Q., Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovascular Research. 43(4):1999;860-878.
16. Joseph G., Zhao Y., Klaus W. Pharmakologisches Wirkprofil von Crataegus-Extrakt im Vergleich zu Epinephrin, Amrinon, Milrinon und Digoxin am isoliert perfundierten Meerschweinchenherzen. Arzneimittel Forschung/Drug Research. 45(12):1995;1261-1265.
17. Kaul R. Der Weißdorn. Botanik, Inhaltsstoffe, Qualitä tskontrolle, Pharmakologie, Toxikologie und Klinik. 1998;Wissenschaftliche Verlagsgesellschaft, Stuttgart.
18. Koch E., Chatterjee S.S. Crataegus extract WS-1442 enhances coronary flow in the isolated rat heart by endothelial relase of nitric oxide. Naunyn-Schmiedeberg's Archives of Pharmacology. 361:2000;R48. (Suppl.).
19. Krzeminski T., Chatterjee S.S. Ischemia and early reperfusion induced arrhythmias: beneficial effects of an extract of Crataegus oxyacantha L. Pharmaceutical and Pharmacological Letters. 3:1993;45-48.
20. Lundergan C.F., Reiner J.S., Ross A.M. How long is too long? Association of time delay to successful reperfusion and ventricular function outcome in acute myocardial infarction: the case for thrombolytic therapy before planned angioplasty for acute myocardial infarction. American Heart Journal. 144(3):2002;456-462.
21. Müller A., Linke W., Klaus W. Crataegus extract blocks potassium currents in guinea pig ventricular cardiac myocytes. Planta Medica. 65(4):1999;335-339.
22. Müller A., Linke W., Zhao Y., Klaus W. Crataegus extract prolongs action potential duration in guinea-pig papillary muscle. Phytomedicine. 3(3):1996;257-261.
23. Parratt J.R. Protection of the heart by ischemic preconditioning: mechanisms and possibilities for pharmacological exploitation. Trends in Pharmacological Sciences. 15(1):1994;19-25.
24. Pöpping S., Rose H., Ionescu I., Fischer Y., Kammermeier H. Effect of a hawthorn extract on contraction and energy turnover of isolated rat cardiomyocytes. Arzneimittel Forschung/Drug Research. 45(11):1995;1157-1161.
25. Rakhit R.D., Marber M.S. Nitric oxide: an emerging role in cardioprotection? Heart. 86(4):2001;368-372.
26. Richard V., Kaeffer N., Thuillez C. Delayed protection of the ischemic heart-from pathophysiology to therapeutic application. Fundamentals in Clinical Pharmacology. 10(5):1996;409-415.
27. Rigelsky J.M., Sweet B.V. Hawthorn: pharmacology and therapeutic uses. American Journal of Health Systems and Pharm. 59(5):2002;417-422.
28. Scalbert A., Williamson G. Dietary intake and bioavailability of polyphenols. Journal of Nutrition. 130(Suppl. 8S):2000;2073S-2085S.
29. Schmidt-Schweda S., von Burstin J., Möllmann H., Wollner S., Holubarsch C. Der positive inotrope Effekt des Crataegus Spezialextrakt WS 1442 in isolierten Myozyten aus menschlichem Vorhof- und Ventrikelmyokard wird vorwiegend durch oligomere Procyanidine vermittelt. Zeitschrift für Kardiologie. 89(Suppl. 5):2000;164.
30. Schwinger R.H., Pietsch M., Frank K., Brixius K. Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. Journal of Cardiovascular Pharmacology. 35(5):2000;700-707.
31. Seligmann C., Bock A., Leitsch T. Polymorphonuclear granulocytes induce myocardial dysfunction during ischemia and in later reperfusion of hearts exposed to low-flow ischemia. Journal of Leukocyte Biology. 69(5):2001;727-731.
32. Upton R. American Herbal Pharmacopoeia and Therapeutic Compendium. Hawthorn Leaf with Flower. Crataegus spp. Analytical, Quality Control, and Therapeutic Monograph. 1999;American Herbal Pharmacopoeia, Santa Cruz.
33. Walker M.J., Curtis M.J., Hearse D.J., Campell R.W., Janse M.J., Yellon D.M., Cobbe S.M., Coker S.J., Harness J.B., Harron D.W., Higgins A.J., Jullian D.G., Lab M.J., Manning A.S., Northover B.J., Parratt J.R., Riemersma R.A., Riva E., Russell D.C., Sheridan D.J., Winslow E., Woodward B. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia, infarction and reperfusion. Cardiovascular Research. 22(7):1988;447-455.
34. Willerson J.T. Pharmacologic approaches to reperfusion injury. Advances in Pharmacology. 39:1997;291-312.